Mantle Cell Lymphoma
News
Acalabrutinib may outperform other targeted therapies in MCL
The drug showed advantages over targeted monotherapies but was similar to rituximab-based combinations.
News
FDA approves Brukinsa for relapsed, refractory MCL
The Bruton tyrosine kinase (BTK) inhibitor zanubrutinib showed high overall response rates in two clinical trials.
News
Survival ‘excellent’ after rituximab-bendamustine induction in transplant-eligible MCL
Investigators reported that the regimen’s efficacy is on par with R-hyperCVAD, but is less toxic.
News
ASCO to award $50,000 young investigator grant to study MCL
The award is a 1-year grant of $50,000 to pursue clinical research on mantle cell lymphoma.
News
Follow-up shows favorable results with acalabrutinib in MCL
The median duration of response exceeded 2 years with acalabrutinib monotherapy.
News
Staging PET/CT better defines extent of mantle cell lymphoma
This type of imaging altered stage and management in nearly one-fifth of cases.
News
Rituximab, bendamustine look better than chemo alone in MCL
The research confirms the benefit of adding novel agents to chemotherapy regimens in older patients with mantle cell lymphoma.
Conference Coverage
Ibrutinib-rituximab induction yields ‘unprecedented’ responses in MCL
LUGANO, SWITZERLAND – In patients younger than 65 years old, two cycles of ibrutinib and rituximab followed by four cycles of chemotherapy...
Conference Coverage
Ibrutinib/rituximab effective, safe as frontline treatment for older patients with MCL
LUGANO, SWITZERLAND –The chemotherapy-free combination was associated with a high objective response rate in patients with a median age of 71...
News
Low-dose radiation therapy looks effective in hard-to-treat MCL
The treatment approach can be used safely with concurrent chemotherapy.